Three clinical and 11 preclinical candidates move beyond traditional enzyme replacement, aim for wider range of patients

How liquid biopsies could lead to the next big step in modeling dose levels for precision medicine.

How Bioverativ solidifies Genzyme as Sanofi’s growth engine

How restructured Alnylam, Sanofi deal generates more value for both companies

What has to happen to implement EMA/FDA proposal for platform trials in rare disease

How Richard Peters plans to keep Genzyme ahead in Orphan diseases

How Gaucher's disease drugs could help multiple myeloma